allergic asthma asthma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Having allergic asthma (step 1-4 according to GINA 2019 guidelines), stable at the moment of inclusion - Have been treated with low or medium dose inhalation corticosteroids in combination with a SABA or LABA, or as-needed low dose ICS-formoterol, or appropriate alternative medication according to the GINA guidelines for at least one year - Aged 18-70 - BMI between 20 and 35 kg/m2 - Willing to abstain from products containing plant sterols and/or stanols one month before and during the study - Willing to keep the intake of fish oil supplements constant during the study
Exclusion criteria
Exclusion criteria: - Currently smoking or quitted smoking in the past year, with a maximum of 10 packyears as smoking history (packyears = packs per day * years of smoking) - Allergy to an ingredient of the soft chews - Treatment with HMG-CoA reductase inhibitors (statins) to lower serum cholesterol - Suffering from inflammatory diseases (for CVD, illness must be minimally 3 years ago and currently under control in order to participate in the study) - Fasting plasma glucose > 7.0 mmol/L - Fasting serum TC > 8.0 mmol/L - Having donated blood within one month prior to the start of the study, or planning to donate blood during the study - Pregnant women - Breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is the change in asthma control questionnaire (ACQ) score from baseline to the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include lung function parameters, markers for immune function, medication use, CVD risk parameters and vaccination response. | — |
Countries
Netherlands